×

Browse

Jazz-Sponsored Symposium – High-risk AML* in 2022: what is the go-to strategy?

Watch Gert Ossenkoppele, Lars Bullinger and Thomas Shroeder present on what is the go-to strategy in high-risk AML in 2022 at the ESH 3rd How to Diagnose and Treat Acute Leukaemias Meeting 

This Jazz Pharmaceuticals sponsored, promotional symposium is intended for healthcare professionals only

Prescribing information and adverse event reporting details are available in the video 

*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

INT-VYX-2200049
Date of Preparation: April 2022